738 related articles for article (PubMed ID: 33743756)
1. "They're not doing enough.": women's experiences with opioids and naloxone in Toronto.
Macleod ER; Tajbakhsh I; Hamilton-Wright S; Laliberte N; Wiese JL; Matheson FI
Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):26. PubMed ID: 33743756
[TBL] [Abstract][Full Text] [Related]
2. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
[TBL] [Abstract][Full Text] [Related]
3. "I don't go to funerals anymore": how people who use opioids grieve drug-related death in the US overdose epidemic.
Schlosser AV; Hoffer LD
Harm Reduct J; 2022 Oct; 19(1):110. PubMed ID: 36183109
[TBL] [Abstract][Full Text] [Related]
4. Naloxone protection, social support, network characteristics, and overdose experiences among a cohort of people who use illicit opioids in New York City.
Bennett AS; Scheidell J; Bowles JM; Khan M; Roth A; Hoff L; Marini C; Elliott L
Harm Reduct J; 2022 Mar; 19(1):20. PubMed ID: 35246165
[TBL] [Abstract][Full Text] [Related]
5. A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.
Spector AL; Galletly CL; Christenson EA; Montaque HDG; Dickson-Gomez J
BMC Public Health; 2022 Jul; 22(1):1387. PubMed ID: 35854278
[TBL] [Abstract][Full Text] [Related]
6. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
[TBL] [Abstract][Full Text] [Related]
7. Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario.
Leece PN; Hopkins S; Marshall C; Orkin A; Gassanov MA; Shahin RM
Can J Public Health; 2013 Apr; 104(3):e200-4. PubMed ID: 23823882
[TBL] [Abstract][Full Text] [Related]
8. Addiction stigma and the production of impediments to take-home naloxone uptake.
Fomiatti R; Farrugia A; Fraser S; Dwyer R; Neale J; Strang J
Health (London); 2022 Mar; 26(2):139-161. PubMed ID: 32529843
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with gaps in naloxone knowledge: evidence from a 2022 great plains survey.
Cooper-Ohm S; Habecker P; Humeniuk R; Bevins RA
Harm Reduct J; 2024 Feb; 21(1):37. PubMed ID: 38336722
[TBL] [Abstract][Full Text] [Related]
10. Access to, Experience with, and Attitudes towards Take Home Naloxone: An Online Survey.
Schwieger L; Carpenter JE; Moran TP; Erowid F; Cornelison M; Evans D; Morgan B; Murray BP
J Community Health; 2024 Jun; 49(3):526-534. PubMed ID: 38127295
[TBL] [Abstract][Full Text] [Related]
11. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic.
Irvine MA; Kuo M; Buxton JA; Balshaw R; Otterstatter M; Macdougall L; Milloy MJ; Bharmal A; Henry B; Tyndall M; Coombs D; Gilbert M
Addiction; 2019 Sep; 114(9):1602-1613. PubMed ID: 31166621
[TBL] [Abstract][Full Text] [Related]
12. "Narcan encounters:" overdose and naloxone rescue experiences among people who use opioids.
Kahn LS; Wozniak M; Vest BM; Moore C
Subst Abus; 2022; 43(1):113-126. PubMed ID: 32243234
[TBL] [Abstract][Full Text] [Related]
13. A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.
Parkin S; Neale J; Brown C; Jones JD; Brandt L; Castillo F; Campbell ANC; Strang J; Comer SD
Int J Drug Policy; 2021 Jan; 87():102968. PubMed ID: 33096365
[TBL] [Abstract][Full Text] [Related]
14. Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.
Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J;
Int J Drug Policy; 2021 Oct; 96():103421. PubMed ID: 34452808
[TBL] [Abstract][Full Text] [Related]
15. Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis.
Antoniou T; McCormack D; Campbell T; Sutradhar R; Tadrous M; Lum-Wilson N; Leece P; Munro C; Gomes T
Drug Alcohol Depend; 2020 Nov; 216():108238. PubMed ID: 32891910
[TBL] [Abstract][Full Text] [Related]
16. "That's why we're speaking up today": exploring barriers to overdose fatality prevention in Indianapolis' Black community with semi-structured interviews.
Seo DC; Satterfield N; Alba-Lopez L; Lee SH; Crabtree C; Cochran N
Harm Reduct J; 2023 Oct; 20(1):159. PubMed ID: 37891632
[TBL] [Abstract][Full Text] [Related]
17. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
McDonald R; Campbell ND; Strang J
Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
[TBL] [Abstract][Full Text] [Related]
18. [Opioid overdose prevention and naloxone diffusion (POP program): Results of an overview conducted among addiction specialized centres].
Mezaache S; Turlure F; Fredon N; Le Brun Gadelius M; Micallef J; Frauger E
Therapie; 2023; 78(6):605-614. PubMed ID: 37012152
[TBL] [Abstract][Full Text] [Related]
19. "A Blessing and a Curse:" Opioid Users' Perspectives on Naloxone and the Epidemic of Opioid Overdose.
Kline A; Mattern D; Cooperman N; Dooley-Budsock P; Williams JM; Borys S
Subst Use Misuse; 2020; 55(8):1280-1287. PubMed ID: 32182153
[No Abstract] [Full Text] [Related]
20. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
